0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > All Other Proteins > CD19 > Human CD19 (20-291) Protein, Fc Tag, low endotoxin

Human CD19 (20-291) Protein, Fc Tag, low endotoxin

  • Synonym
    CD19,B4,CVID3,MGC12802
  • Source
    Human CD19 (20-291), Fc Tag, low endotoxin (CD9-H5259) is expressed from human 293 cells (HEK293). It contains AA Pro 20 - Lys 291 (Accession # AAH06338).
    Predicted N-terminus: Pro 20
  • Molecular Characterization
    Online(Pro 20 - Lys 291) AAH06338

    This protein carries a human IgG1 Fc tag at the C-terminus.

    The protein has a calculated MW of 56.3 kDa. The protein migrates as 56-90 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin
    Less than 0.1 EU per μg by the LAL method.
  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    No activity loss was observed after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Human CD19 (20-291), Fc Tag, low endotoxin (Cat. No. CD9-H5259) SDS-PAGE gel

Human CD19 (20-291), Fc Tag, low endotoxin on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-ELISA
Human CD19 (20-291), Fc Tag, low endotoxinHuman CD19 (20-291), Fc Tag, low endotoxin (Cat. No. CD9-H5259) ELISA bioactivity

Immobilized FMC63 at 1 μg/mL (100 μL/well) can bind Human CD19 (20-291), Fc Tag, low endotoxin (Cat. No. CD9-H5259) with a linear range of 0.039-0.625 μg/mL (QC tested).

Human CD19 (20-291), Fc Tag, low endotoxinHuman CD19 (20-291), Fc Tag, low endotoxin (Cat. No. CD9-H5259) ELISA bioactivity

Immobilized Human CD19 (20-291), Fc Tag, low endotoxin (Cat. No. CD9-H5259) at 5 μg/mL (100 μL/well) can bind FMC63 with a linear range of 0.6-20 ng/mL (QC tested).

Bioactivity-SPR
Human_FcRn_Heterodimer_Protein_SPR

Human CD19 (20-291), Fc Tag, low endotoxin (Cat. No. CD9-H5259) captured on CM5 chip via Anti-Human lgG Fc antibodies surface can bind FMC63 MAb (mouse lgG2a) with an affinity constant of 3.88 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Evaluation of CAR expression
FACS Analysis of anti-CD19 CAR Expression
Evaluation of CAR expression

293 cells were transfected with FCM63-scFv and RFP tag. 2e5 of the cells were first incubated with A. Human Fc tag control. B. Human CD19 (20-291), Fc Tag, low endotoxin (Cat. No. CD9-H5259, 10 μg/mL). C. Human CD19 (20-291), Fc Tag, low endotoxin (Cat. No. CD9-H5259, 10 μg/mL) and FMC63 (Mouse anti-CD19 antibody). The FITC anti-human IgG Fc was used to analyse with FACS. RFP was used to evaluate CAR (FMC63-scFv) expression and FITC was used to evaluate the binding activity of Human CD19 (20-291), Fc Tag, low endotoxin (Cat. No. CD9-H5259).

FACS Analysis of anti-CD19 CAR Expression
Evaluation of CAR expression

Human T cells were lentivirally transduced with anti-CD19 CAR and cultured for 3 days. Three days post-transduction, 1e6 cells were first incubated with 100 μL Human CD19 (20-291), Fc Tag, low endotoxin (Cat. No. CD9-H5259, 10 μg/mL), washed and then stained with PE anti-human IgG Fc Antibody. Non-transduced T cells were used as a control for gating of CAR expression. (Data are kindly provided by XIAMEN Anti-hela Biological TechnologyTrade Co. Ltd.)

Comments (0)

Order Details

Price(USD) : $410.00

Price(USD) : $2400.00

Promotion & Exhibitions

  • PEGS Boston 2019
  • PepTalk 2019

Drug Development Status

  • Number of Launched Drugs:3 Details
  • Number of Drugs in Clinical Trials:153 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

Questions & Comments

This web search service is supported by Google Inc.

totop